Примери за използване на Develop antibodies на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Some people using this medicine can develop antibodies to factor VIII(also known as factor VIII inhibitors).
Although patients could develop antibodies against the medicine, which might reduce its effectiveness, this has not
People who recover from Ebola infection develop antibodies that can last for at least 10 years.
Patients may also develop antibodies to the proteins in TachoSil,
Some patients may develop antibodies(made by your body to fight a foreign protein) to InductOs.
Most people develop antibodies that protect them from these toxins
As with all medicinal products, a small percentage of patients may develop antibodies to the protein somatropin.
They develop antibodies against those fragments of undigested protein,
Patients with acquired haemophilia caused by antibodies against factor VIII may develop antibodies against susoctocog alfa.
The team will look at how well these people develop antibodies against HIV, and also whether
patients may develop antibodies to the therapeutic protein.
People who recover from Ebola infection develop antibodies that last for at least 10 years.
Up to 20% of people develop antibodies to the clotting factors which makes treatment more difficult.
The studies showed that the birds which receive the vaccine develop antibodies against the H5 subtype of the avian influenza virus.
The fact that such a body of the fair sex during each pregnancy develop antibodies.
This cell will produce helper cells that will help the immune system develop antibodies, and there are two types of helper cells.
The all-natural ingredients list existing in Wartrol then develop antibodies which destroy warts.
30% of people develop antibodies to fight against gluten proteins.
A pharmacodynamic model based on the Phase III trial data predicts that around 15% of the patients develop antibodies in 6 months at the recommended dose regimen(200 mg every 2 weeks following a loading dose) without MTX co-treatment.
Immunogenicity data from three long-term clinical studies indicate that approximately one third of patients develop antibodies, as determined by the mouse neutralisation/ mouse protection assay dependent on duration of exposure.